Glioma
Conditions
Brief summary
This project intends to evaluate the role of C-X-C chemokine receptor type 4 (CXCR4) targeted PET/MRI integrated imaging in the grading and molecular typing of brain gliomas, using primary glioma patients as the research subjects and post-operative histopathological analysis as the reference, and to establish an evaluation model for the prognosis of primary glioma patients.
Detailed description
1. PET/MRI Scan: Image acquisition was completed 15 days before surgery. CXCR4 contrast agent was injected at 6.5 MBq/kg based on body mass, with no drug extravasation, and imaging was performed after 60 minutes of quiet rest. All subjects were scanned in a supine position on a single bed of the Signa™ 3.0T scanner (GE Healthcare Systems), using a 3.0T gem HNU head coil with a scanning field of view focused on the head. PET acquisition lasted for 20 minutes and was reconstructed using OSEM. Simultaneous MRI acquisition included MR-based attenuation correction (MRAC) - zero echo time pulse sequence (ZTE), as well as structural and functional MRI sequences (T1WI, T2WI, FLAIR, DWI, MRS, DSC, T1-CE). Image fusion was performed on a GE post-processing workstation. 2. Image Analysis and Observation Indicators: PET/MRI images were independently reviewed and processed by two experienced neuroradiologists. Using IKT-SNAP software, target lesion VOIs were outlined based on FLAIR and T1-CE sequences. VOI delineation on the FLAIR sequence included solid tumor components, necrotic areas, and surrounding abnormal FLAIR signal regions. VOI delineation on the T1-CE sequence included enhanced solid components, non-enhanced solid components, and necrotic areas. MRI parameters (diffusion-weighted imaging parameters: ADC; perfusion imaging parameters: CBF, CBV, MTT, TTP; spectroscopic parameters: NAA, Cho, Cr, Lac, NAA/Cr, Cho/Cr) and PET parameters (SUVmax, SUVmean, SUVpeak, CXCR4 metabolic volume, TBR) were measured throughout the tumor and corresponding regions. 3. Pathological Analysis: Slices containing no less than 25% tumor tissue were used, with each slice having a thickness of 4um. HE, CD34, and CXCR4 immunohistochemical staining were performed separately. Two senior pathologists reviewed the slides using a double-blind method. IDH mutation status and 1p/19q deletion status were determined by the pathology department.
Interventions
DIAGNOSTIC_TESTCXCR4
Patients with clinical suspected primary glioma will receive a CXCR4 PET imaging.
Sponsors
Xiao Chen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed with primary glioma based on clinical, imaging, and histopathological criteria; 2. The patient is at least 18 years old; 3. Participate in CXCR4 PET/MRI imaging within 15 days before surgery; 4. Surgical resection of glioma lesion tissue can be used for pathological analysis; 5. The patient voluntarily participates and signs the informed consent form.
Exclusion criteria
1. Pregnant or breastfeeding patients; 2. The image quality of the imaging is poor and cannot be used for diagnosis and evaluation; 3. Molecular typing was not determined by histologic examination; 4. patients with claustrophobia; 5. Patients who are allergic to radioactive tracers and MRI contrast agents, and patients with renal insufficiency.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Standardised uptake values | completed within one week after the PET/MRI examination | Standardised uptake values of suspected glioma disease in CXCR4 PET/MRI imaging |
| expression of CD34 | completed within one week after surgery | Immunohistochemical evaluation of the expression of CD34 in postoperative tumor tissue |
| expression of CXCR4 | completed within one week after surgery | Immunohistochemical evaluation of the expression of CXCR4 in postoperative tumor tissue |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SUV and histological grading of glioma | through study completion, an average of 1 year | Correlation between SUV and histological grading of glioma |
| SUV and 1p/19q deletion status | through study completion, an average of 1 year | Correlation between SUV and 1p/19q deletion status |
| CXCR4 expression and histological grading of glioma | through study completion, an average of 1 year | Correlation between CXCR4 expression and histological grading of glioma |
| SUV and IDH mutation status | through study completion, an average of 1 year | Correlation between SUV and IDH mutation status |
Countries
China
Contacts
Primary ContactDu ZHenwei, Ph.D
Outcome results
None listed